Announced details
Dental and oral healthcare, regenerative medicine, congenital anodontia, diagnosis, prevention and ongoing care, medical-dental collaboration
Investment through subscription to a third-party allotment of new shares. The parties aim to establish a medium- to long-term strategic partnership.
A Kyoto University spinout startup. Head office: 448-5 Kajii-cho, Kawaramachi Imadegawa-sagaru, Kamigyo-ku, Kyoto; established: 12 May 2020; representative: President and co-founder Kiso Honoka (喜早ほのか); business: research and development of regenerative medicine products specializing in the dental and oral healthcare fields.
Orphan drug designation
448-5 Kajii-cho, Kawaramachi Imadegawa-sagaru, Kamigyo-ku, Kyoto
Going private
The investment is not intended to generate short-term earnings. No specific impact on financial results has been disclosed.
The company does not address Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | TRG035 (humanized anti-USAG-1 antibody) |
| Counterparty | トレジェムバイオファーマ株式会社 |
| Counterparty overview | A Kyoto University spinout startup. Head office: 448-5 Kajii-cho, Kawaramachi Imadegawa-sagaru, Kamigyo-ku, Kyoto; established: 12 May 2020; representative: President and co-founder Kiso Honoka (喜早ほのか); business: research and development of regenerative medicine products specializing in the dental and oral healthcare fields. |
| Relationship with the Company | Investment through subscription to a third-party allotment of new shares. The parties aim to establish a medium- to long-term strategic partnership. |
| Contract Value | Going private |
| Applicable area | Dental and oral healthcare, regenerative medicine, congenital anodontia, diagnosis, prevention and ongoing care, medical-dental collaboration |
| Award/certification name | Orphan drug designation |
| Location | 448-5 Kajii-cho, Kawaramachi Imadegawa-sagaru, Kamigyo-ku, Kyoto |
| Impact on Business Performance | The investment is not intended to generate short-term earnings. No specific impact on financial results has been disclosed. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a strategic investment aimed at becoming involved in the regenerative medicine field at an early stage, exploring potential synergies with adjacent businesses such as diagnostics, prevention and maintenance, and acquiring knowledge relating to medical-dental collaboration and the development of new technologies. It is not intended to generate short-term earnings.